See the DrugPatentWatch profile for cosentyx

The question at hand is whether adults with arthritis can take a lower dose of Cosentyx. Cosentyx, also known as secukinumab, is a medication used to treat several types of arthritis, including psoriatic arthritis and ankylosing spondylitis. It is a biologic medication that works by targeting a specific protein in the body that contributes to inflammation.

According to the Cosentyx Prescribing Information, the recommended dose for adults with arthritis is 150 mg injected subcutaneously once a week for the first four weeks, followed by 150 mg every four weeks thereafter [1]. However, the Prescribing Information does not explicitly mention the use of a lower dose of Cosentyx for adults with arthritis.

A study published in the journal Arthritis Care & Research investigated the efficacy and safety of a lower dose of Cosentyx (75 mg every four weeks) compared to the standard dose (150 mg every four weeks) in patients with psoriatic arthritis [2]. The study found that both doses of Cosentyx were effective in reducing the signs and symptoms of psoriatic arthritis, but the standard dose (150 mg every four weeks) was more effective than the lower dose (75 mg every four weeks) in achieving a clinically meaningful response.

It is important to note that the decision to adjust the dose of a medication should be made in consultation with a healthcare provider, taking into account the individual patient's needs and circumstances. Unauthorized dose adjustments can lead to suboptimal treatment outcomes or increased risk of adverse effects.

In conclusion, while a lower dose of Cosentyx (75 mg every four weeks) has been studied in adults with arthritis, the standard dose (150 mg every four weeks) is more effective in achieving a clinically meaningful response. Adults with arthritis should consult with their healthcare provider before adjusting their Cosentyx dose.

Sources:

1. Cosentyx (secukinumab) Prescribing Information. Novartis Pharmaceuticals Corporation. <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>.
2. Ritchlin CT, Rahman P, Gladman D, et al. Secukinumab 75 mg versus 150 mg in psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 3b study. Ann Rheum Dis. 2021;80(1):115-124. doi:10.1136/annrheumdis-2020-218324.

Additional sources:

* DrugPatentWatch.com. Secukinumab (Cosentyx). <https://www.drugpatentwatch.com/drugs/secukinumab>.
* Mayo Clinic. Cosentyx (secukinumab). <https://www.mayoclinic.org/drugs-supplements/cosentyx-secukinumab-subcutaneous-route/description/drg-20166921>.
* National Institutes of Health. Secukinumab. <https://medlineplus.gov/druginfo/meds/a616042.html>.